These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 34494448)

  • 1. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
    Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
    AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolic activity assessment by
    Kim DY; Lee HW; Kang W; Kim GM; Won JY; Yun M
    J Gastroenterol Hepatol; 2021 Jun; 36(6):1679-1684. PubMed ID: 33226706
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of pre-treatment F-18-FDG PET-CT in patients with hepatocellular carcinoma undergoing radioembolization.
    Abuodeh Y; Naghavi AO; Ahmed KA; Venkat PS; Kim Y; Kis B; Choi J; Biebel B; Sweeney J; Anaya DA; Kim R; Malafa M; Frakes JM; Hoffe SE; El-Haddad G
    World J Gastroenterol; 2016 Dec; 22(47):10406-10414. PubMed ID: 28058021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
    Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT.
    Talbot JN; Gutman F; Fartoux L; Grange JD; Ganne N; Kerrou K; Grahek D; Montravers F; Poupon R; Rosmorduc O
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1285-9. PubMed ID: 16802155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.
    Fartoux L; Balogova S; Nataf V; Kerrou K; Huchet V; Rosmorduc O; Talbot JN
    Nucl Med Commun; 2012 Jul; 33(7):757-65. PubMed ID: 22504293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.
    Wallace MC; Sek K; Francis RJ; Samuelson S; Ferguson J; Tibballs J; Asad A; Preen DB; MacQuillan G; Garas G; Adams LA; Jeffrey GP
    Dig Dis Sci; 2020 Feb; 65(2):647-657. PubMed ID: 31440998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total Lesion Glycolysis on 18F-FDG PET/CT Is a Better Prognostic Factor Than Tumor Dose on 90Y PET/CT in Patients With Hepatocellular Carcinoma Treated With 90Y Transarterial Radioembolization.
    Hwang SH; Hong HS; Kim D; Kim GM; Lee HW; Lee M; Kim DY; Park MA; Yun M
    Clin Nucl Med; 2022 Jun; 47(6):e437-e443. PubMed ID: 35384891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET/CT with
    Filippi L; Bagni O; Notarianni E; Saltarelli A; Ambrogi C; Schillaci O
    Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival in patients with hepatocellular carcinoma treated with 90Y-microsphere radioembolization. Prediction by 18F-FDG PET.
    Sabet A; Ahmadzadehfar H; Bruhman J; Sabet A; Meyer C; Wasmuth JC; Pieper CC; Biersack HJ; Ezziddin S
    Nuklearmedizin; 2014; 53(2):39-45. PubMed ID: 24777354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-choline PET-computed tomography for the prediction of early treatment responses to transarterial radioembolization in patients with hepatocellular carcinoma.
    Aujay G; Debordeaux F; Blanc JF; Lapuyade B; Papadopoulos P; Bordenave L; Trillaud H; Pinaquy JB
    Nucl Med Commun; 2021 Jun; 42(6):633-638. PubMed ID: 33660694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant Value of
    Ho CL; Chen S; Cheung SK; Leung TWT
    PET Clin; 2019 Oct; 14(4):459-467. PubMed ID: 31472743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
    Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
    Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization.
    Bargellini I; Crocetti L; Turini FM; Lorenzoni G; Boni G; Traino AC; Caramella D; Cioni R
    Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1373-1383. PubMed ID: 29654507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioembolization with
    Ho CL; Chen S; Cheung SK; Leung YL; Cheng KC; Wong KN; Wong YH; Leung TWT
    Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2110-2121. PubMed ID: 29948107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.
    Ho CL; Chen S; Yeung DW; Cheng TK
    J Nucl Med; 2007 Jun; 48(6):902-9. PubMed ID: 17504862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of post-Yttrium 90 radioembolization therapy 18F-fluorodeoxyglucose positron emission tomography in patients with liver tumors.
    Obrzut S; McCammack K; Badran KW; Balistreri A; Ou E; Nguyen BJ; Hoh CK; Rose SC
    Clin Imaging; 2017; 42():43-49. PubMed ID: 27875761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of
    Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
    Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of combining ¹¹C-choline and ¹⁸F-FDG PET/CT in hepatocellular carcinoma.
    Castilla-Lièvre MA; Franco D; Gervais P; Kuhnast B; Agostini H; Marthey L; Désarnaud S; Helal BO
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):852-859. PubMed ID: 26577938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.